PLK3 and tuberculosis: Notably, PRK in combination with standard‐of‐care anti‐TB drug, Rif, showed improved results with maximum diminution of lung‐associated Mtb burden and a decrease in CFU by 1 log unit as compared to treatment with Rif alone (Fig 8G).